Pyoderma gangrenosum
Pyoderma gangrenosum nexweşiyek çermî ya nadir, inflamatorî ye ku pûstûl an girêkên bi êş dibin, ulcerên ku bi pêşdeçûn mezin dibin. Pyoderma gangrenosum ne enfeksiyon e. Dibe ku dermankirin bi kortîkosteroîd, ciklosporîn, an antîpên monoklona yên cihêreng were kirin. Her çend ew dikare li her temenê kesan bandorê bike, bi taybetî li mirovên di navbera 40 û 50 salî de zêdetir dîtine.
☆ Di encamên 2022-an de Stiftung Warentest ji Almanyayê, razîbûna xerîdar bi ModelDerm tenê ji şêwirmendên telemedicine drav hindik hindiktir bû.
Li ser lingê kesê bi kolîta ulceratîf.
relevance score : -100.0%
ReferencesPyoderma gangrenosum rewşek çermî ya kêm e ku dibe sedema ulcerên bi êş û keviyên sor an morî. Ew wekî nexweşiyek înflamatuar tê dabeş kirin û beşek ji komeleke ku navê wê dermatozên neutrofîlî ye. Sedema Pyoderma gangrenosum tevlihev e; di nav mirovên ku ji hêla genetîkî ve meylê wan in de, pirsgirêkên hem bi berevaniya xwezayî û hem jî bi adaptasyona xwe re têkildar in. Di demên dawî de, lêkolîner balê dikişînin ser pelika porê wekî xalek destpêka nexweşiyê.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum rewşek çermî ya hindik e ku dibe sedema ulcerên pir bi êş. Dema ku em bi tevahî sedema wê fêm nakin, em dizanin ku ew çalakiya hin hûcreyên berhevaniyê zêde dike. Dermankirina nexweşiyê hîn jî ne hêsan e. Dermanên me yên cihêreng hene ku pergala berhevaniyê ditepisînin an çalakiya wê diguhezînin. Li gel van, em li ser dermankirina birînan û birêvebirina êşan jî disekinin. Corticosteroids û cyclosporine bi gelemperî bijareya yekem ji bo dermankirinê in, lê di demên dawî de, li ser karanîna dermanên biyolojîk ên mîna frendêrên TNF-α bêtir lêkolîn hene. Van dermanên biyolojîkî her ku diçe bêtir têne tercîh kirin, bi taybetî di nexweşên ku şert û mercên înflamatuar ên din hene de, û ew di pêvajoya nexweşiyê de berê têne bikar anîn.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
